HOME >> BIOLOGY >> NEWS
Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University

Snowmass, Co. (September 10, 2004) - Inflammatory Bowel Diseases, comprised of Crohn's Disease and ulcerative colitis, are for the most part incurable and their causes are still unknown. About 1 million Americans suffer from IBD and research around the world on new therapeutic strategies against IBD is being reported at a conference sponsored by the American Physiological Society.

On one thing most researchers agree on about IBD: it's very complex. And though it might seem obvious that treating a complex disease might take more than one agent, use of combination therapy hasn't been discussed much in relation to IBD.

Now separate groups working in Houston/Boston and Jerusalem have considered the implications of combination therapy in IBD. They are presenting their papers at the APS conference.

Intestinal Lactobacillus reuteri-based combination therapy directly modulates mucosal pro-inflammatory cytokine production in IL-10 deficient mice.

Probiotics and commensal bacteria represent likely sources for novel therapeutic strategies in inflammatory bowel diseases, and have become increasingly interesting to researchers. Indeed, some probiotic therapy agents are thought to be nearing the clinical trial stage. It is well-known that the human (and animal) gut is full of mostly beneficial bacteria. In IBD and other diseases researchers have taken an approach that reintroduces these positive bacteria, allow them to repopulate the gut and quite often they produce their own anti-inflammatory chemicals. One of the major such "bugs" is the genus Lactobacillus.

The research reported below was carried by James Versalovic and Jeremy Andrew Pena at the Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, and by Arlin B. Rogers, Zhongming Ge and James G. Fox at the Division of Comparative Medicine at Massachusetts Institute of Technology, Cambridge, Mass.

Probiotics have demonstrated efficacy in treating patients
'"/>


10-Sep-2004


Page: 1 2 3

Related biology news :

1. Winning combination to build bone density in children
2. Complex cells likely arose from combination of bacterial and extreme-microbe genomes
3. Researchers zero in on new drug combination strategy
4. IUB researchers to investigate genetic recombinations causes and consequences
5. Mutated protein combination tied to excessive sugar production
6. Clinical study reports findings of combination therapy with DOXIL
7. Novel COX-2 combination treatment may reduce colon cancer risk
8. Drug combination increases life span of mice with ALS
9. A combination of zinc and vitamin A may restore night vision in pregnant Nepalese women
10. Alcohol and thiamine deficiency together: a dangerous combination?
11. Inter-Element Recombination Between Retrotransposons May Be Strategy For Evolution Of Viruses Like HIV

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/30/2019)... ... September 30, 2019 , ... ... molecular manufacturing and other transformative technologies, announced the winners for the 2019 Foresight ... the other for Theory in nanotechnology/molecular manufacturing. , Established in 1993 and named ...
(Date:9/30/2019)... ... ... As human induced pluripotent stem cells (hiPSCs) move closer to becoming a ... the human heart, there is an increasing need for stable stem cell lines that ... and easily recorded. A study released today in STEM CELLS details the development of ...
(Date:9/30/2019)... Calif. (PRWEB) , ... September ... ... a leading think tank, research, and public interest organization focused on molecular ... Distinguished Student Prize. , The Award recognizes the College graduate or undergraduate ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... , ... October 02, 2019 , ... ... life sciences leadership firm that is enabling clinical program outsourcing success by cultivating ... by award-winning pharma and biotech veteran executive Brenda Reese, phaseUP™ brings clients deep, ...
(Date:10/3/2019)... BOSTON (PRWEB) , ... October 03, 2019 , ... Yesterday, ... 2-3, Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., discussed important ... To an attendee audience including both developers and suppliers of clinical trials, in ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and ... company focused on the development of therapies to treat central nervous system ...
(Date:9/22/2019)... ... 20, 2019 , ... ZRT Laboratory is pleased ... serum . BDNF plays a vital role in protecting existing neurons in the ... neurons in the brain involved in learning, memory, and higher thinking. Low serum ...
Breaking Biology Technology:
Cached News: